Abstract
Aims Patients with non-ischemic dilated cardiomyopathy (DCM) are at considerable risk for end-stage heart failure (HF), requiring close monitoring to identify early signs of disease. We aimed to develop a model to predict the 5-years risk of end-stage HF, allowing for tailored patient monitoring and management.
Methods and results Derivation data were available from a Dutch cohort of 293 DCM patients, with external validation available from a Czech Republic cohort of 235 DCM patients. Candidate predictors spanned patient and family histories, ECG and echocardiogram measurements, and biochemistry. End-stage HF was defined as a composite of death, heart transplantation, or implantation of a ventricular assist device. Lasso and sigmoid kernel support vector machine (SVM) algorithms were trained using cross-validation. During follow-up 65 (22%) of Dutch DCM patients developed end-stage HF, with 27 (11%) cases in the Czech cohort. Out of the two considered models, the lasso model (retaining NYHA class, heart rate, systolic blood pressure, height, R-axis, and TAPSE as predictors) reached the highest discriminative performance (testing c-statistic of 0.85, 95%CI 0.58; 0.94), which was confirmed in the external validation cohort (c-statistic of 0.75, 95%CI 0.61; 0.82), compared to a c-statistic of 0.69 for the MAGGIC score. Both the MAGGIC score and the DCM-PROGRESS model slightly over-estimated the true risk, but were otherwise appropriately calibrated.
Conclusion We developed a highly discriminative risk-prediction model for end-stage HF in DCM patients. The model was validated in two countries, suggesting the model can meaningfully improve clinical decision-making.
Competing Interest Statement
AFS has received funding from NewAmsterdam Pharmaceuticals for unrelated work. AS has received funding from Pfizer and Sanofi Genzyme for unrelated work. RRvdL is co-founder and shareholder of Cordys Analytics.
Funding Statement
AFS is supported by BHF grant PG/18/5033837, PG/22/10989, and the UCL BHF Research Accelerator AA/18/6/34223. AFS, MB, FWA, PL, RP, LS, and PM received grant funding from the EU Horizon scheme (AI4HF 101080430 and DataTools4Heart 101057849). AFS, and FWA received funding from the Dutch Research Council (MyDigiTwin 628.011.213). FWA is supported by UCL Hospitals NIHR Biomedical Research Centre. This work was supported by the Horizon EiC Pathfinder project DCM-NEXT 101115416, the National Institutes of Health (USA) [R01 LM010098] the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking BigData@Heart grant n 116074, as well as by the UKRI/NIHR Multimorbidity fund Mechanism and Therapeutics Research Collaborative MR/V033867/1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the Declaration of Helsinki. In UMCU, the study was reviewed by the institutional ethics review board (Medical Research Ethics Committee (MREC) NedMec, Heidelberglaan 100, 3584 CX Utrecht). The UMCU-cohort participants were included using an opt-out procedure. The UMCU protocol was waived by the MREC from the Medical Research Involving Human Subjects Act (WMO) (18/446 and 19/222, University Medical Center Utrecht, The Netherlands) maintaining the requirement for informed consent. The study was reviewed and approved by the Ethical Committee of the St. Anne's University Hospital Brno, Pekarska 53, 602 00, Brno, with the reference number EK-FNUSA-01/2023. ICRC participants in the study provided written consent for using their data for research purposes.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The derived prediction model is fully described in the supplementary note, with a unit-tested software implementation available on https://gitlab.com/SchmidtAF/DCM-PROGRESS. The underlying patient data is available upon reasonable request and contingent on ethical approval from co-authors Anneline ter Riele (UMCU) and Pavel Leinveber (ICRC).
